'66, if there was even a hint of efficacy from IONIC, NOX wouldn't be disbanding the clinical team. And they wouldn't have recruitment problems. And they wouldn't have a shareprice of 5c.
NOX has no IP and no people left. Just licenses for a couple of preclinical assets from Hudson and a warehouse full of suppositories that no-one wants.
There is no breathing room -- less than two quarters of funding is not breathing room.
NOX Price at posting:
5.9¢ Sentiment: None Disclosure: Not Held
